What is the main concern with cardiotoxicity from anthracyclines?

What is the main concern with cardiotoxicity from anthracyclines?

• A. Liver damage
• B. Heart failure
• C. Nerve damage
• D. Kidney dysfunction

Answer: (B)

The primary concern with cardiotoxicity from anthracyclines revolves around the risk of heart failure. Anthracyclines, such as doxorubicin, are well-known for their potential to cause damage to the heart muscle, leading to various forms of cardiac dysfunction. This effect can manifest as a dose-dependent decrease in cardiac contractility, potentially resulting in heart failure, which can occur during treatment or manifest years after completion of therapy. This cardiotoxicity is primarily attributed to the accumulation of the drug within cardiac myocytes, which leads to oxidative stress, apoptosis, and impaired contractile function. The severity of cardiotoxicity is influenced by cumulative doses, prior heart conditions, and the use of other cardiotoxic agents. Monitoring cardiac function through echocardiograms or other imaging techniques is essential for early detection and management of potential heart failure in patients receiving anthracycline treatment. The other options, such as liver damage, nerve damage, and kidney dysfunction, are not the predominant concerns associated with anthracycline therapy, although they can occur in other chemotherapy treatments or at higher doses in some cases. However, the cardiotoxic risk remains a significant focus in the management of patients receiving anthracycline drugs.

The primary concern with cardiotoxicity from anthracyclines revolves around the risk of heart failure. Anthracyclines, such as doxorubicin, are well-known for their potential to cause damage to the heart muscle, leading to various forms of cardiac dysfunction. This effect can manifest as a dose-dependent decrease in cardiac contractility, potentially resulting in heart failure, which can occur during treatment or manifest years after completion of therapy.

This cardiotoxicity is primarily attributed to the accumulation of the drug within cardiac myocytes, which leads to oxidative stress, apoptosis, and impaired contractile function. The severity of cardiotoxicity is influenced by cumulative doses, prior heart conditions, and the use of other cardiotoxic agents. Monitoring cardiac function through echocardiograms or other imaging techniques is essential for early detection and management of potential heart failure in patients receiving anthracycline treatment.

The other options, such as liver damage, nerve damage, and kidney dysfunction, are not the predominant concerns associated with anthracycline therapy, although they can occur in other chemotherapy treatments or at higher doses in some cases. However, the cardiotoxic risk remains a significant focus in the management of patients receiving anthracycline drugs.